Tretinoin 0.045% | Hydroquinone 6% | Hydrocortisone 2.5%
Tretinoin 0.045% | Hydroquinone 6% | Hydrocortisone 2.5% is a dermatology-focused preparation for prescriber-directed skin protocols. Ingredient selection should reflect the patient's diagnosis, skin type, tolerability, pregnancy status, and treatment goal.
This compounded topical preparation represents the modified Kligman formula—the classical three-component approach to refractory hyperpigmentation—combining tretinoin 0.045% (retinoid for keratinocyte turnover and melanin dispersal), hydroquinone 6% (tyrosinase inhibitor), and hydrocortisone 2.5% (low-potency corticosteroid that reduces treatment-induced inflammation and inhibits prostaglandin-mediated melanocyte activation). The hydrocortisone component helps prevent the post-inflammatory hyperpigmentation that can paradoxically result from the irritation caused by tretinoin and high-concentration hydroquinone. Genesis Compounding prepares this as a prescription-only, patient-specific 503A compounded preparation and it is not FDA-approved as a compounded product.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Tretinoin 0.045% | Retinoic acid receptor agonist that accelerates epidermal turnover, disperses melanin granules, and enhances penetration of co-ingredients. |
| Hydroquinone 6% | Tyrosinase inhibitor that blocks melanin biosynthesis at the L-DOPA conversion step, providing the primary depigmenting mechanism. |
| Hydrocortisone 2.5% | Low-potency glucocorticoid that reduces treatment-induced inflammatory stimulation of melanocytes, inhibits prostaglandin-mediated melanogenesis, and controls retinoid/hydroquinone-associated erythema and irritation. |
Applied topically once nightly to hyperpigmented skin on clean, dry skin. Apply a thin layer to affected areas only; avoid eyes, lips, and nostrils. Use SPF 30+ broad-spectrum sunscreen every morning. Do not use under occlusion unless directed—occlusion increases systemic absorption of both corticosteroid and hydroquinone.
Apply once nightly as prescribed. Standard Kligman-derived regimens limit continuous treatment to 3–6 months due to the cumulative risks of hydroquinone (ochronosis) and corticosteroid (skin atrophy). Prescriber-guided cycling is typical. All dosing decisions are made by the clinician.
- Tretinoin (0.045%): RAR/RXR activation → epidermal renewal, melanin dispersal, procollagen induction, enhanced penetration of hydroquinone through the stratum corneum.
- Hydroquinone (6%): Competitive tyrosinase substrate inhibitor; direct melanocytotoxicity at higher concentrations; reduces both eumelanin and pheomelanin synthesis.
- Hydrocortisone (2.5%): Glucocorticoid receptor agonist that induces lipocortins → inhibits phospholipase A2 → reduces arachidonic acid release → decreases prostaglandin (particularly PGE2) synthesis. PGE2 is a potent melanocyte stimulator; by blocking its production, hydrocortisone interrupts the inflammatory hyperpigmentation cycle. Additionally, hydrocortisone vasoconstricts, reduces erythema, and suppresses the retinoid-induced inflammatory response that can lead to PIH.
The Kligman formula (tretinoin + hydroquinone + corticosteroid) is one of the most studied and clinically proven approaches to melasma and PIH. The 6% hydroquinone/2.5% hydrocortisone compounded concentration provides enhanced depigmenting and anti-inflammatory activity compared to the classic 4%/0.1% formulation, for patients with refractory disease or darker skin phototypes (Fitzpatrick III–VI) where PIH risk is highest.
Monitoring considerations:
- Limit continuous use to 3–6 months; implement a cycling strategy or transition to maintenance therapy
- Monitor for ochronosis (discontinue immediately if blue-black paradoxical pigmentation appears)
- Monitor for corticosteroid skin changes (atrophy, telangiectasias, striae) especially on the face
- Reinforce mandatory daily sunscreen use
Contraindications:
- Hypersensitivity to any component
- Pregnancy (first trimester especially; minimize corticosteroid exposure in all trimesters)
- Active skin infection at application site
- Periorbital area (corticosteroid-induced glaucoma risk)
Warnings & Precautions:
- Ochronosis: prolonged hydroquinone use risk; limit to 3–6 months
- Skin atrophy and striae: hydrocortisone with prolonged or occluded use on the face
- Photosensitivity: mandatory daily sunscreen for all components
- Systemic absorption: hydrocortisone and hydroquinone can absorb systemically; avoid large surface areas and occlusion
Common Side Effects: Erythema, peeling, irritation, and dryness initially; skin atrophy, striae, and telangiectasias with prolonged corticosteroid use.
Store at room temperature (15–25°C) in opaque, sealed packaging protected from light and air. Hydroquinone oxidizes and turns brown when exposed to light or air; discard discolored preparations. Do not freeze. Use within the Genesis Compounding-assigned beyond-use date.
What is the Kligman formula?
The Kligman formula, developed by dermatologist Albert Kligman, combines a retinoid (to increase cell turnover), hydroquinone (to block melanin production), and a corticosteroid (to reduce inflammation) into a single topical preparation for treating melasma. This compounded formula follows the same principle at higher concentrations for resistant cases.
Why is hydrocortisone included if I'm treating hyperpigmentation?
Hydrocortisone is included specifically to prevent the inflammation that drives melanocyte activation. When tretinoin or hydroquinone irritates the skin, that irritation can trigger more pigmentation—especially in darker skin tones. The hydrocortisone prevents this counterproductive cycle.
How long can I use this continuously?
Due to risks of ochronosis (from hydroquinone) and skin thinning (from hydrocortisone), continuous use is generally limited to 3–6 months. Your prescriber will guide you on cycling or maintenance strategies.
Will this cause skin thinning?
Hydrocortisone 2.5% is a low-potency corticosteroid. Skin atrophy is possible with prolonged use or use under occlusion, particularly on the face. Following prescribed application instructions (thin layer, no occlusion, limited duration) minimizes this risk.
Is this FDA-approved?
This is a 503A compounded preparation by Genesis Compounding. The Kligman concept is clinically well established; this specific combination at these concentrations is not FDA-approved as a compounded product.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.